A new technology is set to revolutionize the way doctors assess women suspected of having womb cancer by drastically reducing the number of invasive tests required. The AI-powered blood test, being developed by NHS organizations in England, has shown promising results in clinical trials. According to reports, around 90,000 postmenopausal women are referred each year by general practitioners for checks following heavy bleeding. However, many of these referrals are deemed unnecessary, resulting in thousands of women being unnecessarily subjected to invasive tests.
The AI blood test is designed to identify subtle changes in blood levels that may indicate the presence of womb cancer. The technology has already shown significant potential in reducing unnecessary testing and hospitalization rates. By detecting these anomalies early on, doctors can focus resources on more critical cases while minimizing the risk of false positives. This could lead to a significant reduction in invasive procedures, potentially slashing costs for patients.
Clinical trials are underway, with NHS organizations working closely with researchers to refine and validate the technology. The results from these trials have been promising, suggesting that the AI blood test could reduce invasive womb cancer checks by up to 70%. As the technology continues to advance, it is likely that this approach will become increasingly widespread within the NHS.